Correlation between oxidized low density lipoproteins and von Willebrand factor renal failure

Thrombosis and Haemostasis

Volumn 76, Issue 5, 1996, Pages 663-669

  Holvoet, Paul ^a   Donck, Jan ^b   Landeloos, Michèle ^a   Brouwers, Els ^a   Luijtens, Kristel ^b   Arnout, Jozef ^a   Lesaffre, Emmanuel ^b   Vanrenterghem, Yves ^b   Collen, Désiré ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD ANALYSIS; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONSERVATIVE TREATMENT; CONTROLLED STUDY; ENDOTHELIUM INJURY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0029862474     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650639     Document Type: Article

References (39)

1. Kannel WB. CHD risk factors. A Framingham study update. Hosp Pract 1990; 25: 119-23.
2. Wissler RW. Update on the pathogenesis of atherosclerosis. Am J Med 1990; 91: 3S-9S.
3. Ma KW, Greene EL, Raij L. Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am J Kidney Dis 1992; 19: 505-13.
4. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697-701.
5. Rostand SG, Kirk KA, Rutsky EA. Relationship of coronary risk factors to hemodialysis -associated ischemic heart disease. Kidney Int 1982; 22: 304-8.
6. Rostand SG, Brunzell JD, Cannon RO, Victor RG. Cardiovascular complications in renal failure. J Am Soc Nephrol 1991; 2: 1053-62.
7. Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993; 21: 573-92.
8. Steinberg D, Witztum JL. Lipoproteins and atherogenesis: current concepts. J Am Med Assoc 1990; 264: 3047-52.
9. Ross R. The pathogenesis of atherosclerosis: an update: a perspective for the 1990's. Nature 1993; 362: 801-9.
10. Holvoet P, Collen D. Oxidized lipoproteins in atherosclerosis and thrombosis. FASEB J 1994; 8: 1279-84.
11. Holvoet P, Perez G, Bernar H, Brouwers E, Vanloo B, Rosseneu M, Collen D. Stimulation with a monoclonal antibody (mAb4E4) of scavenger receptor-mediated uptake of chemically modified low density lipoproteins by THP-1 derived macrophages enhances foam cell generation. J Clin Invest 1994; 93: 89-98.
12. Holvoet P, Perez G, Zhao Z, Brouwers E, Bernar H, Collen D. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest 1995; 95: 2611-9.
13. Salonen JT, Ylä-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssonen K, Palinski W, Witztum JL. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 883-7.
14. Maggi E, Bellazzi R, Gazo A, Seccia M, Bellomo G. Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney Int 1994; 46: 869-76.
15. Reidy MA, Chopek M, Chao S, McDonal T, Schwartz SM. Injury induces increase of von Willebrand factor in rat endothelial cells. Am J Pathol 1989; 134: 857-64.
16. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66: 351-5.
17. Degoulet P, Legrain M, Reach I, Aime F, Devries C, Rojas P, Jacobs C. Mortality risk factors in patients treated by chronic hemodialysis. Nephron 1982; 31: 103-10.
18. Neff MS, Eiser AR, Slifkin RF, Baum M, Baez A, Gupta S, Amarga E. Patients surviving 10 years of hemodialysis. Am J Med 1983; 74: 996-1004.
19. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human sera. J Clin Invest 1955; 34: 1345-53.
20. Haberland MD, Fogelman AM, Edwards PA. Specificity of receptor-mediated recognition of malondialdehyde-modified low density lipoproteins. Proc Natl Acad Sci 1982; 79: 1712-6.
21. Steinbrecher UP. Oxidation of low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem 1987; 262: 3603-8.
22. 2 mimics cell-mediated oxidative modification. J Lipid Res 1988; 29: 745-53.
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
24. Reade V, Tailleux A, Reade R, Harduin P, Cachera C, Tacquet A, Fruchart JC, Fievet C. Expression of apolipoprotein B epitopes in low density lipoproteins of hemodialyzed patients. Kidney Int 1993; 44: 1360-5.
25. Hoff HF, O'Neil J. Lesion-derived low density lipoprotein and oxidized low density lipoprotein share a lability for aggregation, leading to enhanced macrophage degradation. Arterioscler Thromb 1991; 11: 1209-22.
26. Steinbrecher UP, Lougheed M. Scavenger-receptor-independent stimulation of cholesterol esterification in macrophages by low density lipoprotein extracted from human aortic intima. Arterioscler Thromb 1992; 12: 608-25.
27. van Berkel TJ, Ziere GJ, Bijsterbosch MK, Kuiper J. Lipoprotein receptors and atherogenic receptor-mediated mechanisms. Curr Opin Lipidol 1994; 5: 331-8.
28. Gonen B, Goldberg AP, Harter RH, Schonfeld G. Abnormal cell-interactive properties of low-density lipoproteins isolated from patients with chronic renal failure. Metabolism 1985; 34: 10-4.
29. Reinhart WH. Shear-dependence of endothelial functions. Experentia 1994; 50: 87-93.
30. Haaber AB, Eidemark I, Jensen T, Feldt-Rasmussen B, Strandgaard S. Vascular endothelial cell function and cardiovascular risk factors in patients with chronic renal failure. J Am Soc Nephrol 1995; 5: 1581-4.
31. Keane WF, Mulcahy WS, Kasiske BL, Kim Y, O'Donnell MP. Hyperlipidemia and progressive renal disease. Kidney Int 1991; Suppl 39: S41-8.
32. Trachtman H, Schwob N, Maesaka J, Valderrama E. Dietary supplementation ameliorates renal injury in chronic puromycin aminonucleoside nephropathy. J Am Soc Nephrol 1995; 5: 1811-9.
33. Steinberg D. Clinical trials of antioxidants in atherosclerosis: are we doing the right thing? Lancet 1995; 346: 36-8.
34. Rasmussen O, Thomsen C, Ingerslev J, Hermansen K. Decrease of von Willebrand factor levels after a high-monounsaturated fat diet in non-insulin-dependent diabetic subjects. Metabolism 1994; 43: 1406-9.
35. Blann AD, Jackson P, Bath PM, Watts GF. von Willebrand factor, a possible indicator of endothelial cell damage, decreases during long-term compliance with a lipid-lowering diet. J Intern Med 1995; 237, 557-61.
36. Reverter JC, Escolar G, Sanz C, Cases A, Villamor N, Nieuwenhuis HK, Lopez J, Ordinas A. Platelet activation during hemodialysis measured through exposure of P-selectin: analysis by flow cytometric and ultrastructural techniques. J Lab Clin Med 1994; 124: 79-85.
37. Zwaginga JJ, Koomans HA, Sixma JJ, Rabelink TJ. Thrombus formation and platelet-vessel wall interaction in the nephrotic syndrome under flow conditions. J Clin Invest 1994; 93: 204-11.
38. Zhao B, Dierichs R, Harrachruprecht B, Winterhorff H. Oxidized LDL induces serotonin release from blood platelets. Am J Hematol 1995; 48: 285-7.
39. Pocock SJ. Subgroup analysis, In: Clinical trial. A practical approach. Pocock SJ, ed. Wiley J & Sons, Chichester, 1993; pp 211-8.